FOLH1 and prostate cancer: According to the meta-analysis by Treglia et al. [119], which included six investigations with a total of 645 patients with biochemically recurrent prostate cancer, [18F]PSMA-1007 and [18F]DCFPyL have similar detection rates dependent on PSA levels, and each has noted advantages over [68Ga]Ga-PSMA-11.